banner

ALRT - ALR Technologies, Inc. back to homepage

ALR Technologies Partners with Mid-America Coalition in Bid to Commercialize Diabetes Management Program ALR Technologies Partners with Mid-America Coalition in Bid to Commercialize Diabetes Management Program(0)

ALR Technologies Inc. (OTCBB: ALRT) took a big step in the direction of commercializing their Health-e-Connect Diabetes Management Program with news this week that the company has partnered with the Mid-America Coalition on Health Care, or MACHC.  The new pact means that MACHC will be introducing the ALRT program for pilot participation by its membership, which consists of 67 organizations representing more than 500,000 employees in the greater Kansas City area. Read More

ALR Technologies Names Former Pfizer Exec as Chief Commercial Officer ALR Technologies Names Former Pfizer Exec as Chief Commercial Officer(0)

Health information company ALR Technologies, Inc. (OTCBB: ALRT) on Monday disclosed the appointment of William S. Smith as Chief Commercial Officer and member of the Board of Directors, effective January 1, 2013.  Smith will oversee sales and marketing, investor relations, public affairs, communications and Read More

Diabetes News Highlights Global Pandemic and Millions of Dollars Wasted Diabetes News Highlights Global Pandemic and Millions of Dollars Wasted(0)

The prevalence and costs associated with diabetes, the most expensive chronic disease in the world, are simply staggering and are coming under heavy scrutiny to adopt changes to better curtail spending and slow the disease’s growth rate.  It doesn’t take an economics or finance degree to realize that savings related to taming the prevalence and containing costs could be into the tens of billions of dollars each year.

In a report late in 2011, the International Diabetes Federation predicted Read More

ALR Technologies Adds Board Members, Readies for Commercialization ALR Technologies Adds Board Members, Readies for Commercialization(0)

Following news from last week that it has completed the development phase for its Health-e-Connect system, a universal platform for remote monitoring of chronic disease, ALR Technologies (OTCBB: ALRT) said this morning that it has added new members to its Board of Directors.  The company also reported that board member and VP of Technology Jaroslav V. Tichy, PhD, will be retiring from those positions and now serve as a consultant to ALRT.  Tichy, who is now 71 years old, played a key role Read More

ALR Technologies Nears Commercialization of Diabetes Management Systems ALR Technologies Nears Commercialization of Diabetes Management Systems(0)

Following an announcement earlier this month providing shareholders with an update on the commercial launch of its Health-e-Connect system for remote monitoring and chronic disease management, ALR Technologies released news today further detailing its systems, including a unique universal cable.  As part of the introduction of the universal cable, Read More

Greater Adherence to Diabetes Management Plans Could Save Billions Greater Adherence to Diabetes Management Plans Could Save Billions(0)

An abstract was recently published on the Health Affairs website title, “Greater Adherence To Diabetes Drugs Is Linked To Less Hospital Use And Could Save Nearly $5 Billion Annually”.  The abstract, written by Ashish K. Jha, an associate professor of health policy at the Harvard School of Public Health and an associate professor of medicine at Harvard Medical School, et al. offers commentary on the substantial benefits of improving adherence to medication for both reducing costs and Read More

ALRT Gears Up for Commercialization of Diabetes Management System ALRT Gears Up for Commercialization of Diabetes Management System(0)

ALR Technologies Updates Shareholders on Commercial Launch of Diabetes Management System

ALR Technologies Inc. (OTCBB: ALRT) (the “Company”), a health information technology company, is pleased to provide shareholders with an update for its FDA-cleared Health-e-Connect System (“the System”) for remote monitoring and chronic disease management. Read More

Taglich Updates ALR Technologies, Maintains 50 Cent Price Target Taglich Updates ALR Technologies, Maintains 50 Cent Price Target(0)

Analyst firm Taglich Brothers has updated their research report on ALR Technologies (OTCBB: ALRT). The New York-based firm has maintained their 50 cent, 12-month price target on ALRT and “Speculative Buy” rating based on five-year revenue potential for the company. Shares of ALRT closed trading on Wednesday at $0.0795; ahead 13.57% from Tuesday’s closing price. Read More

ALR Technologies Stock Chart Analysis Video ALR Technologies Stock Chart Analysis Video(0)

A look at the three-year weekly chart for ALR Technologies (OTCBB: ALRT) shows a baseline pattern and support at 6 cents with additional support at 7 cents. Higher lows have been progressively made over the three years with a top-end resistance at 24 cents. The chart is just above Read More

Taglich Brothers Analyst Report on ALRT in PowerPoint Taglich Brothers Analyst Report on ALRT in PowerPoint(0)

Leading research firm Taglich Brothers has initiated coverage on ALR Technologies, Inc. (OTCBB: ALRT) with a 12-month price target set at 50 cents.  Shares are trading today at 8 cents.  ALR maintains a relatively low profile in the investment community, but Taglich apparently sees some substantial upside based on their extensive analyst report. Read More



Stay Informed

Receive the OTCS Newsletter *




*

* required

Dana-Farber to Host Cellceutix Trials

Cellceutix Corporation (CTIX)
Cellceutix Corporation has filed its Investigational New Drug application with the FDA. Dana-Farber and Beth Israel Deaconess Medical Center will be hosting the clinical trials for Kevetrin, Cellceutix's novel cancer drug. Read more news and get a stock quote.

Diabetes Rate Growing Exponentially

According to the International Diabetes Federation, more than 500 million people will be diagnosed with diabetes in the next two decades, a more than 50 percent increase from today. Technologies are available presently to help manage the frequency, complications and costs associated with diabetes. Read the complete article to learn more.

Contacts and information

Have an opinion or news that you want to share?

Social networks

Most popular categories

Disclaimer/Disclosure
© 2011 Viper Enterprises, LLC. All rights reserved.